Thu, Sep 18, 2014, 8:35 AM EDT - U.S. Markets open in 55 mins.

Recent

% | $
Quotes you view appear here for quick access.

ADVANCED CELL TECH Message Board

  • ssndt88 ssndt88 Aug 25, 2009 10:12 PM Flag

    I'm sick of this Lanza this Lanza that....

     

    I don't give a rats ass if he shets gold! They need to worry about moving this company to .OB!

    You all insider wanna be ass wipes need to shut your freakn' suck!!!!

    You all do DO NOT KNOW A GODDAMN SHIT!!!!!!

    This topic is deleted.
    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • So far its just a rumor about FDA approval.

      Viral Genetics Inc.'s FDA Filing Going Viral
      PRWeb
      posted: 7 HOURS 21 MINUTES AGO

      The Dean of CollegeStock.com announced a mandatory study session for all CollegeStock.com Honors Students as a result of recent article discussing Viral Genetics Inc.'s (Pink Sheets: VRAL) Investigatory New Drug (IND) filing with the FDA.

      New York, NY (PRWEB) August 26, 2009 -- The Dean of CollegeStock.com announced a mandatory study session for all Honors Students as a result of the recent article in Today's Financial News referencing Viral Genetics Inc. (Pink Sheets: VRAL) Investigatory New Drug (IND) filing with the FDA.

      The article, "TFN Reader Grapevine: There's Something about Viral Genetics, Inc. (VRAL)" was published on Tuesday afternoon right as Viral Genetics shares rose as much as 30% on trading volume 1,000% higher than the 10-day average.

      According to the article, "rumor has it that they are planning something big - heard about them filing with the FDA re: investigatory new drug filing within the month."

      "This is the first publicly available information referencing Viral Genetics Inc.'s (VRAL) IND filing with the FDA for their VGV-1 drug and its important that students know all the facts about the FDA process," added Dean.

      The Dean is urging anyone interested in learning more about the IND filing and FDA approval process for Viral's VGV-1 drug to sign up to become an Honors Student at .

      About Viral Genetics:
      Viral Genetics (Pink Sheets: VRAL) discovers and develops drug therapies to treat infectious, autoimmune, and immunological deficiency disorders using its thymus nuclear protein compound (TNP). The company recently entered into an Exclusive License Agreement with the University of Colorado and V-Clip Pharmaceuticals (a subsidiary of the Company) to license technology developed by M. Karen Newell, Ph. D., which appears to explain TNP and provide a means to optimize therapies based on TNP for future clinical trials. Visit www.viralgenetics.com for more information.

    • Just watching here wicks. Does VRAL have wheels?

    • Tobflipped,

      I hope you waited.

      UBRG at $.20. Wait for support to buy back in.

      Good long play but short term profit takers after the big run.

    • agreed wicks, glad to see you got in EXPH too. It's an interesting play.

    • Me too, night guy's

    • got an early morning, you guys have a great night!

    • bhahahahahaaaa

    • roflmao,,,,sorry evil, didnt mean to steal your material! my bad!

    • aahhhh man wicks, I wont have time to watch the start in the morning, have to start a big job. you got me all thinking about it now! lol now I wont be able to sleep!

    • GL Dyo,

      Just watch the first few minutes and see what it does. It's positive that the high was $.45 and then it finished at $.32 so it retraced some. But when a stock climbs so fast with so much volume a 50% retrace could be in the cards.

      If it doesn't hold you could see a sell down to $.23. The first hour will give you a good read.

    • View More Messages
 
ACTC
0.08150.0000(0.00%)Aug 27 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.